{"pmid":32436148,"title":"Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.","text":["Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.","Breast Cancer Res Treat","O'Shaughnessy, Joyce","32436148"],"journal":"Breast Cancer Res Treat","authors":["O'Shaughnessy, Joyce"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436148","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s10549-020-05674-7","topics":["Treatment"],"weight":1,"_version_":1667521393833541632,"score":9.490897,"similar":[]}